Spasticity, following the neurological disorder of cerebral palsy (CP), describes a
pathological condition, the central feature of which is involuntary and prolonged muscle …

Spasticity, following the neurological disorder of cerebral palsy (CP), describes a
pathological condition, the central feature of which is involuntary and prolonged muscle …

Botulinum toxin A (BTX‐A) is increasingly being used in early management of spasticity in
ambulant children with cerebral palsy (CP), with the aim of improving function, promoting …

The aim of this article is to describe our clinical experience in treating muscle imbalance in
49 children with spastic upper extremity involvement. We discuss four cohorts of children …

Purpose The purpose of this review is to clarify the role of botulinum toxin serotype A (BTX-
A) in the treatment of children with cerebral palsy (CP), with a special focus on the lower …

CP is the most common cause of chronic disability in childhood occurring in 2–2.5/1000
births. It is a severe disorder and a significant number of patients present cognitive delay …

Children with spastic cerebral palsy (SCP) are often treated with intramuscular Botulinum
Neurotoxin type-A (BoNT-A). Recent studies demonstrated BoNT-A-induced muscle atrophy …

Cerebral palsy describes a group of disorders of movement and posture that result from
disturbances in the developing brain. Although the brain lesion is nonprogressive, the …

Purpose: Investigate the combination effects of strength training and Botulinum Toxin Type-A
(BoNT-A) on muscle strength and morphology in children with Cerebral Palsy (CP) …

Introduction Spasticity has been considered to be a main contributor to both the impairment
of function as well as posture in children with cerebral palsy (CP). Patterns of upper limb …